Ophthalmology News and Research

RSS

Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.

AIO first in the Pittsburgh area to offer laser surgery for cataract removal

Associates in Ophthalmology (AIO), an eye care and surgery practice with seven locations in the Tri-State Area, has become the region's first medical group to offer bladeless, computer-controlled laser surgery for cataract removal.

23 Jun 2012

Cerebral damage risks vision in children born prematurely

Cerebral damage and retinopathy of prematurity are independently associated with the risk for visual impairment in 4-year-old children who were born prematurely, show Danish study results.

22 Jun 2012

Cheaper drug to treat wet AMD increases risk of serious eye inflammation

A Queen's University study of two eye drugs used to treat wet Age-related Macular Degeneration (AMD) has determined the cheaper of the two could lead to eye inflammation, a potentially blinding adverse effect.

19 Jun 2012

Positive results from Salutaris’ episcleral brachytherapy trial on Wet AMD

Positive results from a trial of episcleral brachytherapy to treat Wet Age-related Macular Degeneration (Wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference.

15 Jun 2012

Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD

Ophthotech Corporation today announced results from the first clinical trial to show statistically significant superior efficacy over Lucentis (ranibizumab) monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD).

14 Jun 2012

Investigational Insomnia Medicine from Merck improved patients’ ability to fall and stay asleep according to new phase III Data

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

13 Jun 2012

Telephone intervention improves medication adherence in patients with glaucoma

A telephone intervention trial was associated with improvement in glaucoma medication adherence in both the treatment group and the control group but, when the two groups were compared, interactive telephone calls and tailored print materials did not significantly improve adherence, according to a report of a randomized controlled clinical trial published Online First by Archives of Ophthalmology, a JAMA Network publication.

13 Jun 2012

Viewpoints: Praise for insurers' move to keep consumer protections; Supreme Court's reputation falters

UnitedHealthcare, one of the nation's largest health insurers, announced this week that it would keep some of the popular benefits and consumer protections required by the federal health care law even if the Supreme Court strikes down all or part of it. ... But such voluntary actions are not a substitute for the broader mandatory reforms that will take effect after 2014 under the law.

13 Jun 2012

Cerebral damage, ROP may increase risk of visual impairment in extremely preterm children

Cerebral damage and retinopathy of prematurity appear to be independently associated with visual impairment among preschool children who were born extremely premature, according to a report published Online First by Archives of Ophthalmology, a JAMA Network publication.

13 Jun 2012

RVO advances PresbyLens into final phase of trial for treatment of presbyopia

ReVision Optics, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, announces the advancement of its proprietary product PresbyLens into the final phase of its U.S. clinical trial under an Investigational Device Exemption

12 Jun 2012

VisionCare expands CentraSight telescope implant provider teams

VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.

8 Jun 2012

Nrf2-KEAP1 protein may play a role in diabetic retinopathy

A Wayne State University researcher believes a protein that fails to reach the nucleus of retinal cells may play a role in causing eye disease in people with diabetes.

8 Jun 2012

Ocular pulse amplitude reliable, safe screening test for carotid artery stenosis

A simple eye test may someday offer an effective way to identify patients who are at high risk for stroke, say researchers at the University of Zurich. They showed that a test called ocular pulse amplitude (OPA) can reliably detect carotid artery stenosis (CAS), a condition that clogs or blocks the arteries that feed the front part of the brain.

8 Jun 2012

CDI introduces MyCell Services

Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell Services.

7 Jun 2012

Study investigates optical treatments to slow myopia progression in children

Research by an optometrist at the University of Houston (UH) supports the continued investigation of optical treatments that attempt to slow the progression of nearsightedness in children.

6 Jun 2012

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

ThromboGenics NV and co-development partner BioInvent International announce today that they will regain global rights to TB-403 from Roche.

6 Jun 2012

BioInvent, ThromboGenics announce results from TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban, an oral anticoagulant.

5 Jun 2012

New 'ESASO Course Series' for ophthalmologists

In the new book series 'ESASO Course Series', the essentials of the courses of the European School for Advanced Studies in Ophthalmology (ESASO) are made available to interested ophthalmologists, optometrists, technicians and residents all over the world.

1 Jun 2012

Mayo Clinic offers new technology for treatment of dry eye

Mayo Clinic in Arizona is the first medical center in Arizona and the Southwest to provide a new technology that treats dry eye by targeting blocked eyelid glands. Blocked glands can inhibit production of oil that is necessary for healthy tears needed to lubricate the eyes.

31 May 2012

DHA prevents age-related vision loss in lab tests

An omega-3 fatty acid found in fish, known as DHA, prevented age-related vision loss in lab tests, demonstrates recently published medical research from the University of Alberta.

31 May 2012